≡ Risteys
R10

Documentation Changelog GitHub Contact & Feedback

Secondary polycythaemia

DOID EFO MESH Endpoint Browser PheWeb

D3_SCNDPOLYCYTHAEMIA

polycythemia: Abnormally high mass or concentration of red blood cells in the blood, either due to an increase in erythropoiesis or a decrease in plasma volume.

Endpoint definition

↥
FinnGen phenotype data

429209 individuals

diagram downward connector

Apply sex-specific rule None

429209

diagram downward connector

Check conditions None

429209

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, registry filters

Hospital Discharge: ICD-10 D75.1
Hospital discharge: ICD-9 2890
Hospital discharge: ICD-8 28900
Cause of death: ICD-10 D75.1
Cause of death: ICD-9 2890
Cause of death: ICD-8 28900

2 out of 7 registries used, show all original rules.

677

diagram downward connector

Check minimum number of events None

677

diagram downward connector

Include endpoints None

677

diagram downward connector
diagram bullet diagram downward connector

Remove individuals based on genotype QC

657

diagram downward connector
D3_SCNDPOLYCYTHAEMIA

Control definitions

Control exclude D3_BLOODOTHER

Extra metadata

Level in the ICD hierarchy 4
First used in FinnGen datafreeze DF2
Parent code in ICD-10 D75
Name in latin Polycythaemia secundaria

Summary Statistics

↥

Key figures

All Female Male
Number of individuals 657 215 442
Unadjusted prevalence (%) 0.16 0.09 0.24
Mean age at first event (years) 56.44 55.92 56.69

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.09 4.40 [2.68, 7.22] 4.5e-9 104
15 years 0.02 2.70 [1.61, 4.52] 1.6e-4 54
5 years 0.00 3.43 [2.15, 5.47] 2.5e-7 31
1 year 0.00 6.63 [3.43, 12.82] 1.9e-8 12

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: D3_SCNDPOLYCYTHAEMIA – Secondary polycythaemia
GWS hits: 1

Survival analyses between endpoints

↥

Plot

before Secondary polycythaemia
after Secondary polycythaemia

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Secondary polycythaemia

↥

Endpoint not on priority list, no data to show.